.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,044,480

« Back to Dashboard

Claims for Patent: 9,044,480

Title:Compositions and methods for treating HCV
Abstract: The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.
Inventor(s): Pilot-Matias; Tami (Green Oaks, IL), Gaultier; Isabelle A. (Libertyville, IL), Tripathi; Rakesh L. (Palatine, IL), Collins; Christine A. (Skokie, IL), Cohen; Daniel E. (Highland Park, IL), Bernstein; Barry M. (Mequon, WI)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/412,167
Patent Claims: 1. A method of treating a HCV patient harboring R155 or D168 resistant mutants, comprising administering to said patient at least 150 mg/day of Compound I or a pharmaceutically acceptable salt thereof, and at least 50 mg/day of ritonavir or a pharmaceutically acceptable salt.

2. The method of claim 1, wherein said method comprises administering to said patient 200 mg/day of Compound I or a pharmaceutically acceptable salt thereof, and 100 mg/day of ritonavir or a pharmaceutically acceptable salt.

3. The method of claim 1, further comprising administering to said patient another anti-HCV agent selected from: a HCV polymerase inhibitor, a NS5A inhibitor, a cyclophilin inhibitor, a CD81 inhibitor, or an internal ribosome entry site inhibitor.

4. A method of treating a treatment-experienced HCV patient who has failed a prior treatment using another protease inhibitor due to emergence of at least one resistant mutation, the method comprising administering to said patient at least 150 mg/day of Compound I or a pharmaceutically acceptable salt thereof, and at least 50 mg/day of ritonavir or a pharmaceutically acceptable salt.

5. The method of claim 4, wherein said method comprises administering to said patient 200 mg/day of Compound I or a pharmaceutically acceptable salt thereof, and 100 mg/day of ritonavir or a pharmaceutically acceptable salt.

6. The method of claim 4, further comprising administering to said patient another anti-HCV agent selected from: a HCV polymerase inhibitor, a NS5A inhibitor, a cyclophilin inhibitor, a CD81 inhibitor, or an internal ribosome entry site inhibitor.

7. A method of treating a HCV patient having non-CC IL28B rs12979860 genotype, comprising administering to said patient at least 150 mg/day of Compound I or a pharmaceutically acceptable salt thereof, and at least 50 mg/day of ritonavir or a pharmaceutically acceptable salt.

8. The method of claim 7, wherein said method comprises administering to said patient 200 mg/day of Compound I or a pharmaceutically acceptable salt thereof, and 100 mg/day of ritonavir or a pharmaceutically acceptable salt.

9. The method of claim 7, further comprising administering to said patient another anti-HCV agent selected from: a HCV polymerase inhibitor, a NS5A inhibitor, a cyclophilin inhibitor, a CD81 inhibitor, or an internal ribosome entry site inhibitor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc